Kura Oncology (NASDAQ:KURA) Insider Sells $51,662.05 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Brian Powl sold 4,345 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.89, for a total transaction of $51,662.05. Following the transaction, the insider owned 169,269 shares of the company’s stock, valued at approximately $2,012,608.41. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kura Oncology Trading Down 3.9%

NASDAQ:KURA opened at $13.06 on Thursday. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -3.88 and a beta of 0.38. Kura Oncology, Inc. has a 52 week low of $7.36 and a 52 week high of $13.90. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a 50 day moving average of $10.74 and a 200 day moving average of $9.58.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. As a group, sell-side analysts anticipate that Kura Oncology, Inc. will post -3.23 earnings per share for the current fiscal year.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. IFP Advisors Inc raised its stake in shares of Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after purchasing an additional 1,284 shares during the last quarter. Allworth Financial LP boosted its position in Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after buying an additional 1,553 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock worth $60,000 after buying an additional 1,888 shares during the period. Tower Research Capital LLC TRC increased its holdings in Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after buying an additional 9,958 shares during the period. Finally, Brevan Howard Capital Management LP purchased a new position in Kura Oncology during the 2nd quarter worth approximately $80,000.

Key Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: CEO Troy Wilson reportedly purchased 100,000 shares for approximately $1.24 million, a sizable open-market investment that investors may interpret as confidence in Kura’s growth prospects. Kura Oncology shares jump after CEO buys $1.24 million of stock
• Positive Sentiment: Analysts continue to express optimism, with Citizens JMP reiterating a “Market Outperform” rating. Broader coverage shows a consensus “Moderate Buy” rating and an average price target of $25.40, materially above recent trading levels. Citizens JMP reiterates Market Outperform rating
• Positive Sentiment: Kura’s commercial outlook is being supported by KOMZIFTI (ziftomenib), which generated $9.1 million in net product revenue over its first two quarters, including 57% sequential growth. Potential expansion into first-line acute myeloid leukemia could substantially increase the addressable market. Phase 1b data are expected in the second half of 2026, with Phase 3 KOMET-017 topline results targeted for 2028. Kura Oncology: Strong Buy and ziftomenib AML expansion prospects
• Positive Sentiment: Recent earnings exceeded expectations: quarterly revenue was $20.87 million versus a $20.16 million consensus estimate, while the per-share loss was narrower than forecast. Institutional ownership also increased, including a large position expansion by California State Teachers’ Retirement System.
• Neutral Sentiment: The company remains unprofitable, with analysts expecting a full-year loss, so valuation remains dependent on continued KOMZIFTI sales growth and successful clinical development.
• Negative Sentiment: Insider Brian Powl sold 4,345 shares worth approximately $51,662. The sale was relatively small and reduced his holdings by 2.5%, but it contrasts with the CEO’s much larger purchase. Kura Oncology insider share sale

Wall Street Analyst Weigh In

Several research analysts recently issued reports on KURA shares. Citizens Jmp reaffirmed a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research report on Monday. CLSA set a $24.00 price target on Kura Oncology in a research note on Thursday, June 4th. Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a report on Monday. Finally, Raymond James Financial set a $24.00 price objective on shares of Kura Oncology in a research report on Monday. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.40.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.